Stephens Investment Management Group LLC raised its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 336.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,130,854 shares of the medical equipment provider's stock after purchasing an additional 871,949 shares during the quarter. Stephens Investment Management Group LLC owned 1.89% of AxoGen worth $47,405,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Lisanti Capital Growth LLC acquired a new position in AxoGen in the second quarter valued at $4,183,000. Edmond DE Rothschild Holding S.A. purchased a new stake in AxoGen during the second quarter valued at about $1,469,000. TimesSquare Capital Management LLC acquired a new stake in AxoGen during the second quarter worth about $31,863,000. Rice Hall James & Associates LLC acquired a new stake in AxoGen during the second quarter worth about $3,414,000. Finally, SummitTX Capital L.P. acquired a new stake in AxoGen during the first quarter worth about $7,769,000. 80.29% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other news, Director Joseph Tyndall sold 3,500 shares of AxoGen stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the sale, the director directly owned 10,650 shares of the company's stock, valued at approximately $529,305. The trade was a 24.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.44% of the company's stock.
AxoGen Price Performance
AXGN opened at $56.95 on Thursday. The company has a fifty day simple moving average of $43.78 and a 200 day simple moving average of $40.76. The firm has a market cap of $3.40 billion, a price-to-earnings ratio of -87.62 and a beta of 1.21. AxoGen, Inc. has a twelve month low of $23.61 and a twelve month high of $59.72. The company has a current ratio of 12.02, a quick ratio of 10.67 and a debt-to-equity ratio of 0.04.
AxoGen (NASDAQ:AXGN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.45 million. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. Equities research analysts expect that AxoGen, Inc. will post -0.36 EPS for the current fiscal year.
Analyst Ratings Changes
AXGN has been the topic of several research analyst reports. Wall Street Zen raised AxoGen from a "buy" rating to a "strong-buy" rating in a research note on Monday. Lake Street Capital reissued a "buy" rating and set a $58.00 target price on shares of AxoGen in a research report on Thursday, October 29th. Morgan Stanley downgraded shares of AxoGen to a "hold" rating in a research report on Tuesday, September 29th. Wells Fargo & Company raised their price target on shares of AxoGen from $48.00 to $56.00 and gave the company an "overweight" rating in a report on Thursday, October 29th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of AxoGen in a research report on Thursday, July 30th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, AxoGen has a consensus rating of "Moderate Buy" and an average price target of $57.92.
View Our Latest Analysis on AxoGen
AxoGen Company Profile
(
Free Report)
AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company's offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.
Recommended Stories
Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.